FREENOME BUSINESS MODEL CANVAS TEMPLATE RESEARCH
Freenome Business Model Canvas: Playbook for Scaling Precision Oncology Diagnostics
Unlock the full strategic blueprint behind Freenome's business model-this concise Business Model Canvas maps value propositions, customer segments, key partners, and revenue levers to show how the company scales precision oncology diagnostics; download the complete Word/Excel files for a section-by-section playbook ideal for investors, strategists, and founders seeking actionable competitive insight.
Partnerships
Strategic Commercialization Agreement with Exact Sciences
In August 2025 Freenome signed an exclusive $885 million U.S. license with Exact Sciences for its colorectal-cancer blood test, unlocking Exact's 400 health systems and 260,000 ordering physicians to drive rapid adoption.
Freenome keeps rights to multi-cancer combinations and gains access to Exact's payer network-supporting reimbursement scale across an addressable U.S. screening market of ~150 million adults and potential annual revenues in the hundreds of millions.
Global Distribution and R&D Alliance with Roche
Freenome signed a strategic collaboration with Roche in November 2025, a deal worth over $200 million to commercialize Freenome's screening tests internationally and grant Roche exclusive ex‑U.S. rights to develop kitted, decentralized processing versions.
The partners are co‑developing multiomic analysis using Roche's Elecsys assays and Sequencing by Expansion (SBX); the collaboration targets regulatory filings across Europe and Asia and aims to scale projected ex‑U.S. test volume to hundreds of thousands annually.
AI Infrastructure Partnership with NVIDIA
Announced January 2026, Freenome partners with NVIDIA to run fragment-level deep learning (FLDL) on NVIDIA accelerated computing and BioNeMo, targeting removal of data-loading bottlenecks and a planned open-source methylation foundational model.
NVIDIA GPUs cut training time; Freenome reports a 3.5x inference speed gain and aims to improve sensitivity for early-stage cancer signals by ~12% while supporting projected R&D cost savings of $8-12M in FY2025.
Health System and Research Network Collaborations
Freenome leverages partnerships with 200+ clinical sites for its 40,000‑participant PREEMPT CRC study to validate performance and real‑world utility, and works with Morehouse School of Medicine and Oracle Cerner to boost trial diversity and EMR integration ahead of 2026 LDT launches.
- 200+ clinical sites
- 40,000 participants (PREEMPT CRC)
- Partners: Morehouse School of Medicine, Oracle Cerner
- Goal: 2026 lung and multi‑cancer LDT launches
Biopharma Alliances for Biomarker Discovery
Freenome partners with Merck KGaA and Siemens Healthineers to use its multiomics platform for identifying molecular signatures in non‑small cell lung cancer and breast cancer, targeting treatment response prediction and MRD (measurable residual disease) monitoring.
The collaborations convert Freenome's 2025 datasets-covering >50,000 patient samples and generating recurring data‑license revenue projected at $45M in 2025-into assets for drug development and precision medicine.
- Merck KGaA: NSCLC signatures, cohort >12,000 samples
- Siemens Healthineers: breast cancer MRD assays, validation n≈8,500
- Multiomics platform: >50,000 total samples (2025)
- Data licensing revenue: $45M projected (2025)
Freenome's 2025 partner push: $1.1B+ deals, 40k PREEMPT CRC, $45M data rev
Freenome's 2025 partnerships (Exact Sciences $885M US license; Roche >$200M ex‑US deal; NVIDIA AI; Merck KGaA, Siemens) scale commercial access, R&D, and data revenue->40k PREEMPT CRC, >50k samples, $45M data revenue, FY2025 $8-12M R&D savings.
| Partner | Deal/Scope | Key metric |
|---|---|---|
| Exact Sciences | $885M US license | 400 systems, 260k physicians |
| Roche | >$200M ex‑US | scale to 100s k tests |
| NVIDIA | AI infra | 3.5x inference, $8-12M saved |
| Clinical sites | PREEMPT CRC | 200+ sites, 40k pts |
| Data partners | Merck, Siemens | >50k samples, $45M rev |
What is included in the product
Detailed Word Document
A concise Business Model Canvas for Freenome mapping customer segments, value propositions, channels, revenue streams, key partners, activities, resources, cost structure, and metrics, reflecting its genomics-based cancer screening strategy and commercialization roadmap for investors and strategists.
Customizable Excel Spreadsheet
High-level, editable Business Model Canvas tailored to Freenome's oncology diagnostics-condenses R&D, partnerships, revenue streams, and regulatory pathways into a one-page snapshot to speed strategy, investor briefs, and cross-functional alignment.
Activities
Multiomics Platform Development and AI Refinement
Freenome integrates genomic, epigenomic, and proteomic data via its AI/ML FLDL platform, scaling models in 2026 to process billions of datapoints per sample to boost APL (advanced precancerous lesion) sensitivity above the current 13.7% baseline.
Regulatory Submission and FDA Liaison
Regulatory Submission and FDA Liaison: Freenome is managing the PMA for SimpleScreen CRC after its final module submission in Q4 2025, targeting FDA approval in H2 2026 and budgeting ~$45-55M for approval-related activities and trials.
Large-Scale Clinical Validation Studies
Freenome runs large prospective trials-most notably PREEMPT CRC with >40,000 average-risk enrollees-and in 2025 continues PROMISE plus multiple MCD trials to generate evidence for guideline inclusion.
These studies target CMS coverage thresholds, aiming for sensitivity/specificity metrics that support reimbursement and drove Freenome to spend an estimated $120-140M on clinical validation through FY2025.
Automated Laboratory Operations and Scaling
Freenome is scaling automated CLIA lab workflows to support a 2026 launch of multiple blood-based tests, targeting capacity to process ~1.2 million samples annually by FY2025 investments and cut turnaround to 24-48 hours.
The common processing backbone supports a menu of personalized assays, aiming for >99% analytic precision and operating sites designed for high throughput and regulatory compliance.
- FY2025 capital spend ~ $120M for lab automation and facilities
- Target capacity ~1.2M samples/year by 2026
- Turnaround time goal 24-48 hours
- Analytic precision target >99%
- CLIA-certified sites for regulatory compliance
Commercial Infrastructure Build-out and Market Access
Following its $330 million SPAC merger in early 2026, Freenome is scaling its commercial team and cloud data stack to drive payer coverage and point-of-care adoption; priority tasks are CMS reimbursement pursuit and contracting with major private payers to capture Medicare's ~64M beneficiaries.
They're integrating result reports into primary-care workflows and EMRs (Epic, Cerner) to shorten time-to-action; pilot integrations in 2025 covered ~120 primary-care sites and processed ~18,500 patient reports.
- SPAC proceeds: $330 million (early 2026)
- Medicare pool: ~64 million beneficiaries
- 2025 pilots: 120 sites, 18,500 reports
- EMR targets: Epic and Cerner integrations
Freenome scales FLDL AI, $330M SPAC fuels 1.2M‑sample labs, 24-48h TAT, >99% precision
Freenome scales its FLDL AI to integrate multi-omic data, funds PMA/clinical programs (~$120-140M validation, $45-55M approval spend), builds CLIA labs (FY2025 capex ~$120M) to handle ~1.2M samples/yr, aims 24-48h TAT and >99% analytic precision; post-SPAC $330M backing fuels commercial, CMS and EMR (Epic/Cerner) integrations (120 sites, 18.5k reports).
| Metric | 2025/Target |
|---|---|
| SPAC proceeds | $330M |
| Clinical validation spend | $120-140M |
| PMA/approval budget | $45-55M |
| Lab capex FY2025 | $120M |
| Capacity target | 1.2M samples/yr |
| TAT | 24-48 hrs |
| Analytic precision | >99% |
| Pilot sites/reports | 120 sites / 18,500 reports |
Preview Before You Purchase
Business Model Canvas
The document you're previewing is the actual Freenome Business Model Canvas you'll receive-no mockups or samples-formatted and ready to use; after purchase you'll download this same complete file for editing, presenting, and sharing.
Product Information
Product Information
Shipping & Returns
Shipping & Returns
Description
Freenome Business Model Canvas: Playbook for Scaling Precision Oncology Diagnostics
Unlock the full strategic blueprint behind Freenome's business model-this concise Business Model Canvas maps value propositions, customer segments, key partners, and revenue levers to show how the company scales precision oncology diagnostics; download the complete Word/Excel files for a section-by-section playbook ideal for investors, strategists, and founders seeking actionable competitive insight.
Partnerships
Strategic Commercialization Agreement with Exact Sciences
In August 2025 Freenome signed an exclusive $885 million U.S. license with Exact Sciences for its colorectal-cancer blood test, unlocking Exact's 400 health systems and 260,000 ordering physicians to drive rapid adoption.
Freenome keeps rights to multi-cancer combinations and gains access to Exact's payer network-supporting reimbursement scale across an addressable U.S. screening market of ~150 million adults and potential annual revenues in the hundreds of millions.
Global Distribution and R&D Alliance with Roche
Freenome signed a strategic collaboration with Roche in November 2025, a deal worth over $200 million to commercialize Freenome's screening tests internationally and grant Roche exclusive ex‑U.S. rights to develop kitted, decentralized processing versions.
The partners are co‑developing multiomic analysis using Roche's Elecsys assays and Sequencing by Expansion (SBX); the collaboration targets regulatory filings across Europe and Asia and aims to scale projected ex‑U.S. test volume to hundreds of thousands annually.
AI Infrastructure Partnership with NVIDIA
Announced January 2026, Freenome partners with NVIDIA to run fragment-level deep learning (FLDL) on NVIDIA accelerated computing and BioNeMo, targeting removal of data-loading bottlenecks and a planned open-source methylation foundational model.
NVIDIA GPUs cut training time; Freenome reports a 3.5x inference speed gain and aims to improve sensitivity for early-stage cancer signals by ~12% while supporting projected R&D cost savings of $8-12M in FY2025.
Health System and Research Network Collaborations
Freenome leverages partnerships with 200+ clinical sites for its 40,000‑participant PREEMPT CRC study to validate performance and real‑world utility, and works with Morehouse School of Medicine and Oracle Cerner to boost trial diversity and EMR integration ahead of 2026 LDT launches.
- 200+ clinical sites
- 40,000 participants (PREEMPT CRC)
- Partners: Morehouse School of Medicine, Oracle Cerner
- Goal: 2026 lung and multi‑cancer LDT launches
Biopharma Alliances for Biomarker Discovery
Freenome partners with Merck KGaA and Siemens Healthineers to use its multiomics platform for identifying molecular signatures in non‑small cell lung cancer and breast cancer, targeting treatment response prediction and MRD (measurable residual disease) monitoring.
The collaborations convert Freenome's 2025 datasets-covering >50,000 patient samples and generating recurring data‑license revenue projected at $45M in 2025-into assets for drug development and precision medicine.
- Merck KGaA: NSCLC signatures, cohort >12,000 samples
- Siemens Healthineers: breast cancer MRD assays, validation n≈8,500
- Multiomics platform: >50,000 total samples (2025)
- Data licensing revenue: $45M projected (2025)
Freenome's 2025 partner push: $1.1B+ deals, 40k PREEMPT CRC, $45M data rev
Freenome's 2025 partnerships (Exact Sciences $885M US license; Roche >$200M ex‑US deal; NVIDIA AI; Merck KGaA, Siemens) scale commercial access, R&D, and data revenue->40k PREEMPT CRC, >50k samples, $45M data revenue, FY2025 $8-12M R&D savings.
| Partner | Deal/Scope | Key metric |
|---|---|---|
| Exact Sciences | $885M US license | 400 systems, 260k physicians |
| Roche | >$200M ex‑US | scale to 100s k tests |
| NVIDIA | AI infra | 3.5x inference, $8-12M saved |
| Clinical sites | PREEMPT CRC | 200+ sites, 40k pts |
| Data partners | Merck, Siemens | >50k samples, $45M rev |
What is included in the product
Detailed Word Document
A concise Business Model Canvas for Freenome mapping customer segments, value propositions, channels, revenue streams, key partners, activities, resources, cost structure, and metrics, reflecting its genomics-based cancer screening strategy and commercialization roadmap for investors and strategists.
Customizable Excel Spreadsheet
High-level, editable Business Model Canvas tailored to Freenome's oncology diagnostics-condenses R&D, partnerships, revenue streams, and regulatory pathways into a one-page snapshot to speed strategy, investor briefs, and cross-functional alignment.
Activities
Multiomics Platform Development and AI Refinement
Freenome integrates genomic, epigenomic, and proteomic data via its AI/ML FLDL platform, scaling models in 2026 to process billions of datapoints per sample to boost APL (advanced precancerous lesion) sensitivity above the current 13.7% baseline.
Regulatory Submission and FDA Liaison
Regulatory Submission and FDA Liaison: Freenome is managing the PMA for SimpleScreen CRC after its final module submission in Q4 2025, targeting FDA approval in H2 2026 and budgeting ~$45-55M for approval-related activities and trials.
Large-Scale Clinical Validation Studies
Freenome runs large prospective trials-most notably PREEMPT CRC with >40,000 average-risk enrollees-and in 2025 continues PROMISE plus multiple MCD trials to generate evidence for guideline inclusion.
These studies target CMS coverage thresholds, aiming for sensitivity/specificity metrics that support reimbursement and drove Freenome to spend an estimated $120-140M on clinical validation through FY2025.
Automated Laboratory Operations and Scaling
Freenome is scaling automated CLIA lab workflows to support a 2026 launch of multiple blood-based tests, targeting capacity to process ~1.2 million samples annually by FY2025 investments and cut turnaround to 24-48 hours.
The common processing backbone supports a menu of personalized assays, aiming for >99% analytic precision and operating sites designed for high throughput and regulatory compliance.
- FY2025 capital spend ~ $120M for lab automation and facilities
- Target capacity ~1.2M samples/year by 2026
- Turnaround time goal 24-48 hours
- Analytic precision target >99%
- CLIA-certified sites for regulatory compliance
Commercial Infrastructure Build-out and Market Access
Following its $330 million SPAC merger in early 2026, Freenome is scaling its commercial team and cloud data stack to drive payer coverage and point-of-care adoption; priority tasks are CMS reimbursement pursuit and contracting with major private payers to capture Medicare's ~64M beneficiaries.
They're integrating result reports into primary-care workflows and EMRs (Epic, Cerner) to shorten time-to-action; pilot integrations in 2025 covered ~120 primary-care sites and processed ~18,500 patient reports.
- SPAC proceeds: $330 million (early 2026)
- Medicare pool: ~64 million beneficiaries
- 2025 pilots: 120 sites, 18,500 reports
- EMR targets: Epic and Cerner integrations
Freenome scales FLDL AI, $330M SPAC fuels 1.2M‑sample labs, 24-48h TAT, >99% precision
Freenome scales its FLDL AI to integrate multi-omic data, funds PMA/clinical programs (~$120-140M validation, $45-55M approval spend), builds CLIA labs (FY2025 capex ~$120M) to handle ~1.2M samples/yr, aims 24-48h TAT and >99% analytic precision; post-SPAC $330M backing fuels commercial, CMS and EMR (Epic/Cerner) integrations (120 sites, 18.5k reports).
| Metric | 2025/Target |
|---|---|
| SPAC proceeds | $330M |
| Clinical validation spend | $120-140M |
| PMA/approval budget | $45-55M |
| Lab capex FY2025 | $120M |
| Capacity target | 1.2M samples/yr |
| TAT | 24-48 hrs |
| Analytic precision | >99% |
| Pilot sites/reports | 120 sites / 18,500 reports |
Preview Before You Purchase
Business Model Canvas
The document you're previewing is the actual Freenome Business Model Canvas you'll receive-no mockups or samples-formatted and ready to use; after purchase you'll download this same complete file for editing, presenting, and sharing.
